QIAGEN receives FDA clearances for Rotor-Gene Q MDx instrument and compatible Influenza A/B assay
. - Both products receive 510(k) clearance for in vitro diagnostic use in the U.S. - Rotor-Gene Q MDx platform offers…
. - Both products receive 510(k) clearance for in vitro diagnostic use in the U.S. - Rotor-Gene Q MDx platform offers…
. - Diagnostic workflow for C. difficile is launched in Europe and submitted in the U.S. for 510(k) clearance as the fi…
. - U.S. submission of therascreen® EGFR RGQ PCR Kit is paired with FDA submission of afatinib, an investigational tyro…
. - U.S. launch of therascreen® KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110,000…
Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $…
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has entered into an agreement with the Ins…
. - Solid performance in second quarter of 2012: Net sales rise 9% (+14% CER) to $307.2 million on growth in all custom…